Eiji Nakano
Overview
Explore the profile of Eiji Nakano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hatta N, Ogata D, Asai J, Maekawa T, Ito T, Takenouchi T, et al.
Exp Dermatol
. 2024 Feb;
33(2):e15030.
PMID: 38375900
Information about extramammary Paget's (EMPD) treatment is limited because of the rarity of the disease. The prognosis differs between in situ EMPD and invasive EMPD; therefore, therapy should be planned...
12.
Namikawa K, Nakano E, Ogata D, Yamazaki N
J Dermatol
. 2024 Feb;
51(3):343-352.
PMID: 38358050
Immune checkpoint inhibitors have been shown to prolong survival of patients with several types of cancer, and the finding was first established in melanoma. Previously, systemic therapy for advanced melanoma...
13.
Wada S, Nakano E, Nakajima M, Kishikawa S, Yoshida A, Mori T, et al.
J Dermatol
. 2024 Jan;
51(6):e196-e197.
PMID: 38217368
No abstract available.
14.
Wada S, Ogata D, Kashihara T, Okuma K, Eto H, Nakano E, et al.
Cancer Med
. 2023 Dec;
12(24):21933-21943.
PMID: 38083908
Background: Melanoma brain metastasis (MBM) has a poor prognosis, although recent treatments, including immune checkpoint inhibitors and targeted therapy, have improved the prognosis. However, these systemic therapies have been reported...
15.
Kawamoto S, Shinkawa E, Fujiwara S, Oda Y, Jimbo H, Nakano E, et al.
Medicine (Baltimore)
. 2023 Nov;
102(46):e36134.
PMID: 37986310
Introduction: The healing of recurrent and refractory skin ulcers requires a long time, during which there is risk of infection, and hospital admission is occasionally required for surgical or daily...
16.
Wada S, Watanabe T, Ishii T, Ichinose Y, Rikitake R, Ogata D, et al.
Cancer Med
. 2023 Oct;
12(23):21364-21372.
PMID: 37902245
Background: Sentinel lymph node biopsy (SLNB) underuse has been reported for skin cancers; however, actual performance rates have not been compared. The objective of this study was to investigate the...
17.
Tsuruta S, Ogata D, Namikawa K, Nakano E, Hiki K, Okumura M, et al.
Int J Clin Oncol
. 2023 Oct;
28(12):1690-1696.
PMID: 37801154
Background: Cutaneous apocrine carcinoma (CAC) is a rare adnexal carcinoma. Limited data exists on the demographics and overall survival (OS) of patients with CAC; thus, there is no consensus on...
18.
Namikawa K, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, Ohe S, et al.
Cancer Med
. 2023 Aug;
12(17):17967-17980.
PMID: 37584204
Background: Anti-PD-1-based immunotherapy is considered a preferred first-line treatment for advanced BRAF V600-mutant melanoma. However, a recent international multi-center study suggested that the efficacy of immunotherapy is poorer in Asian...
19.
Omura G, Namikawa K, Sakai T, Eguchi K, Matsumoto Y, Sakai A, et al.
Jpn J Clin Oncol
. 2023 Aug;
53(11):1045-1050.
PMID: 37551022
Background: Head and neck mucosal melanomas are rare malignancies. Although the prognosis is poor owing to the high incidence of distant metastases, locoregional control remains important. It is difficult to...
20.
Nakayama Y, Ogata D, Wada S, Tsuruta S, Matsui Y, Okumura M, et al.
J Dermatol
. 2023 Jul;
50(11):e396-e397.
PMID: 37458156
No abstract available.